DK1948620T3 - Dihydrogenphosphatsalt af en prostaglandin-2D-receptorantagonist - Google Patents

Dihydrogenphosphatsalt af en prostaglandin-2D-receptorantagonist

Info

Publication number
DK1948620T3
DK1948620T3 DK06825836.7T DK06825836T DK1948620T3 DK 1948620 T3 DK1948620 T3 DK 1948620T3 DK 06825836 T DK06825836 T DK 06825836T DK 1948620 T3 DK1948620 T3 DK 1948620T3
Authority
DK
Denmark
Prior art keywords
prostaglandin
receptor antagonist
dihydrogen phosphate
phosphate salt
salt
Prior art date
Application number
DK06825836.7T
Other languages
English (en)
Inventor
Beverly Langevin
Edward Orton
Daniel Sherer
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Application granted granted Critical
Publication of DK1948620T3 publication Critical patent/DK1948620T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK06825836.7T 2005-10-13 2006-10-12 Dihydrogenphosphatsalt af en prostaglandin-2D-receptorantagonist DK1948620T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72629005P 2005-10-13 2005-10-13
PCT/US2006/039901 WO2007047378A2 (en) 2005-10-13 2006-10-12 Dihydrogen phosphate salt of a prostaglandin d2 receptor antagonist

Publications (1)

Publication Number Publication Date
DK1948620T3 true DK1948620T3 (da) 2013-06-24

Family

ID=37963090

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06825836.7T DK1948620T3 (da) 2005-10-13 2006-10-12 Dihydrogenphosphatsalt af en prostaglandin-2D-receptorantagonist

Country Status (35)

Country Link
US (1) US7642249B2 (da)
EP (1) EP1948620B1 (da)
JP (1) JP2009511591A (da)
KR (1) KR101365480B1 (da)
CN (1) CN101287714B (da)
AR (1) AR058085A1 (da)
AU (1) AU2006304187B2 (da)
BR (1) BRPI0617311A2 (da)
CA (1) CA2625563C (da)
CR (1) CR9870A (da)
DK (1) DK1948620T3 (da)
DO (2) DOP2006000220A (da)
EC (1) ECSP088362A (da)
ES (1) ES2409833T3 (da)
GT (1) GT200600457A (da)
HN (1) HN2008000603A (da)
HR (1) HRP20130341T1 (da)
IL (1) IL190673A (da)
MA (1) MA30005B1 (da)
MY (1) MY145648A (da)
NI (1) NI200800116A (da)
NO (1) NO20082072L (da)
NZ (1) NZ567433A (da)
PE (1) PE20070791A1 (da)
PL (1) PL1948620T3 (da)
PT (1) PT1948620E (da)
RS (1) RS52799B (da)
RU (1) RU2419614C2 (da)
SI (1) SI1948620T1 (da)
TN (1) TNSN08131A1 (da)
TW (1) TW200728288A (da)
UA (1) UA93062C2 (da)
UY (1) UY29862A1 (da)
WO (1) WO2007047378A2 (da)
ZA (1) ZA200802586B (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2005000795A (es) * 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
DOP2007000068A (es) * 2006-04-12 2007-10-31 Sanofi Aventis Us Llc Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2
JP2009539881A (ja) * 2006-06-09 2009-11-19 アイコス コーポレイション Ｄｐ−２アンタゴニストとしての置換フェニル酢酸
ATE531699T1 (de) * 2007-06-29 2011-11-15 Sanofi Sa Verfahren zur herstellung von 2-(3-ä6-ä2-(2,4-
US8067445B2 (en) 2008-02-01 2011-11-29 Panmira Pharmaceuticals, Llc N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
US8497381B2 (en) 2008-02-25 2013-07-30 Panmira Pharmaceuticals, Llc Antagonists of prostaglandin D2 receptors
GB2463788B (en) * 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en) 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors
US8524748B2 (en) 2008-10-08 2013-09-03 Panmira Pharmaceuticals, Llc Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
US20100112606A1 (en) * 2008-10-17 2010-05-06 Michael Armstrong Measurement and analysis of leukotrienes
AR074776A1 (es) * 2008-12-18 2011-02-09 Sanofi Aventis Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
WO2011014587A2 (en) 2009-07-31 2011-02-03 Amira Pharmaceuticals, Inc. Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
KR20120047273A (ko) 2009-08-05 2012-05-11 판미라 파마슈티칼스, 엘엘씨 Ｄｐ2 길항제 및 이의 용도
EP2590640A1 (en) 2010-07-08 2013-05-15 Ramot at Tel-Aviv University Ltd Use of fts and analogs to treat non-autoimmune-allergic and non-allergic inflammatory conditions
EP2621276B1 (en) * 2010-09-30 2017-12-27 Merck Sharp & Dohme Corp. 2-alkoxy pyrimidine pde10 inhibitors
EP2912458B1 (en) 2012-10-24 2018-07-18 NYU Winthrop Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
JP6770522B2 (ja) 2015-02-13 2020-10-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 全身性エリテマトーデスを予防し、及び／又は、治療するためのｐｔｇｄｒ−１及び／又はｐｔｇｄｒ−２アンタゴニスト
DK3302448T3 (da) 2015-06-04 2024-02-05 Aurigene Oncology Ltd Erstattede heterocyclylafledninger som cdk-inhibitore
KR20200109293A (ko) 2017-09-13 2020-09-22 프로제너티, 인크. 자간전증 바이오마커 및 관련된 시스템 및 방법
WO2021113710A1 (en) 2019-12-04 2021-06-10 Progenity, Inc. Assessment of preeclampsia using assays for free and dissociated placental growth factor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711888A (en) * 1985-07-24 1987-12-08 Pfizer Inc. Hydroxy and alkoxy pyrimidines
ATE466581T1 (de) * 2001-12-07 2010-05-15 Vertex Pharma Verbindungen auf pyrimidin-basis als gsk-3-hemmer
KR100768609B1 (ko) * 2003-07-09 2007-10-18 에프. 호프만-라 로슈 아게 티오페닐아미노이미다졸린
HN2005000795A (es) 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2

Also Published As

Publication number Publication date
HRP20130341T1 (en) 2013-05-31
EP1948620A2 (en) 2008-07-30
HK1125133A1 (en) 2009-07-31
IL190673A (en) 2011-12-29
CA2625563C (en) 2011-04-19
EP1948620B1 (en) 2013-03-20
PL1948620T3 (pl) 2013-08-30
SI1948620T1 (sl) 2013-05-31
CR9870A (es) 2008-06-18
DOP2006000223A (es) 2007-05-15
WO2007047378A2 (en) 2007-04-26
IL190673A0 (en) 2008-11-03
CA2625563A1 (en) 2007-04-26
RU2419614C2 (ru) 2011-05-27
MA30005B1 (fr) 2008-12-01
MY145648A (en) 2012-03-15
RS52799B (sr) 2013-10-31
NZ567433A (en) 2010-06-25
ECSP088362A (es) 2008-05-30
KR20080057275A (ko) 2008-06-24
UA93062C2 (ru) 2011-01-10
PT1948620E (pt) 2013-05-06
UY29862A1 (es) 2007-05-31
BRPI0617311A2 (pt) 2011-07-19
KR101365480B1 (ko) 2014-02-21
ZA200802586B (en) 2009-09-30
ES2409833T8 (es) 2013-09-26
NI200800116A (es) 2011-12-15
JP2009511591A (ja) 2009-03-19
CN101287714B (zh) 2011-04-06
WO2007047378A3 (en) 2007-08-02
AU2006304187A1 (en) 2007-04-26
AU2006304187B2 (en) 2011-04-28
US7642249B2 (en) 2010-01-05
RU2008118491A (ru) 2009-11-20
US20080194600A1 (en) 2008-08-14
PE20070791A1 (es) 2007-08-16
TW200728288A (en) 2007-08-01
AR058085A1 (es) 2008-01-23
NO20082072L (no) 2008-05-02
HN2008000603A (es) 2010-11-03
DOP2006000220A (es) 2007-05-15
CN101287714A (zh) 2008-10-15
ES2409833T3 (es) 2013-06-28
TNSN08131A1 (en) 2009-07-14
GT200600457A (es) 2007-04-27

Similar Documents

Publication Publication Date Title
CR9870A (es) Dihydrogen phosphate salt of a prostaglandin d2 recptor antagonist
FIC20230039I1 (fi) Sedatsuridiini tai tämän farmaseuttisesti hyväksyttävä suola
FR22C1030I1 (fr) Formes cristallines d'un inhibiteur de la prolyle hydroxylase
FIC20240046I1 (fi) Vibegroni tai sen farmaseuttisesti hyväksyttävä suola
NO2022057I1 (no) Capmatinib or a pharmaceutically acceptable salt thereof
FIC20240041I1 (fi) Aprositentaani tai sen farmaseuttisesti hyväksyttävä suola
BRPI0913930A2 (pt) antagonistas de receptores de prostaglandinas d2
DK2152879T3 (da) RNA antagonistforbindelser til modulering af beta-catenin
EP2854859A4 (en) CRYSTALLINE FORMS OF A BRUTON TYROSINE KINASE HEATHER
DK1962817T3 (da) Transdermal tilførsel af et salt af meptazinol
DK2066628T3 (da) 2-Phenylindoler som antagonister af prostaglandin-D2-receptorer
BRPI0811156A2 (pt) compostos antagonistas de rna para a modulação de her3
FR2939815B1 (fr) Bloc a bancher pour la construction de mur
DK2021486T4 (da) System til fremstilling af bioorganiske forbindelser
BRPI1008829A2 (pt) forma cristalina de dihidrogenofosfato de (r)-3-(4-(2-(2-metiltetrazol-5-il) piridin-5-il)-3-fluorofenil)-5-hidroximetil oxazolidin-2-ona
BRPI0714764A2 (pt) Derivados substituídos de sulfonamida
DK1856050T3 (da) Krystallinske former af en biphenylforbindelse
BRPI0810926A2 (pt) Antagonista de crig
BRPI0819902A2 (pt) C2-c5-alquil-imidazol-bifosfonatos
PT2146944E (pt) Processo para a preparação de folatos marcados com 18f
DK2307435T3 (da) Salte af HIV-inhibitorforbindelser
BRPI0914531A2 (pt) "método para a preparação de um polimorfo a"
ITPR20070098A1 (it) Procedimento per idratare un terreno coesivo mediante elettrosmosi perimpedirne la riduzione volumetrica per disidratazione
PL1723157T3 (pl) Amorficzne postaci rizedronianu monosodowego
ITMI20051989A1 (it) Procedimerntyo per la preparazione di composti antagonisti di angiotensina ii